SEC Form 8-K Summary
Registrant: Priveterra Acquisition Corp. (in connection with AEON Biopharma, Inc.)
Report date: February 24, 2023
Reporting period: The filing reports a corporate disclosure event, not quarterly or annual financial results.
Business Context and Event
AEON Biopharma published the final presentation from a key opinion leader webinar addressing past, present, and potential future treatments for migraine using botulinum toxin. The webinar was held on February 24, 2023. The presentation was furnished as Exhibit 99.1.
Financial Metrics and Capitalization
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
- The filing does not include financial statements or quantitative guidance.
- Securities listed for Priveterra Acquisition Corp. included units, Class A common stock, and redeemable warrants on Nasdaq.
Material Changes Versus Prior Period
No financial or operating changes versus a prior comparable period are reported. The principal update is the publication of the webinar presentation.
Guidance, Outlook, Risks, and Unusual Items
- The filing does not provide formal management guidance or financial outlook.
- The webinar concerned potential future migraine treatments using botulinum toxin; the filing text does not provide clinical, regulatory, commercial, or efficacy conclusions from the presentation.
- Information under Item 7.01, including Exhibit 99.1, was furnished rather than filed and is not deemed incorporated by reference into other filings.
- The registrant stated that the disclosure would not be deemed an admission regarding the materiality of the information.
Key Facts for Investor Verification
- Verify the contents and conclusions of Exhibit 99.1, which is not included in the provided filing text.
- Confirm the relationship and transaction context between Priveterra Acquisition Corp. and AEON Biopharma, Inc.
- Review separate filings for AEON’s financial condition, clinical development status, regulatory risks, financing needs, and transaction updates.
- Do not interpret this 8-K as reporting financial results or new quantitative guidance.